cagrilintide starting dose Dosage: 10 mg Vial cagrilintide with retatrutide dosage CagriSema

10.1111/all.14852 278 StepanovaM.ClementS.WongR.SaabS.AhmedA.YounossiZ

Background There were two GLP-1 products that were initially approved and marketed for treating type-2 diabetes but, because they also had successful weight loss results, the manufacturers each got FDA approval to sell the products under two separate indications, one indicated for type 2 diabetes and one for weight loss, each with its own brand name and National Drug Code (NDC) identification number

The peptide upregulates MMP-2 expression in dermal fibroblasts by 85%, facilitating breakdown of damaged collagen and enabling cellular migration through dense matrix environments, while simultaneously enhancing production of tissue inhibitors of metalloproteinases (TIMPs) to prevent excessive degradation

Treatment decisions are based on clinical judgment, patient history, and safety considerations